Merck’s Postmarketing Study Delays Prompt FDA To Unsheathe New Enforcement Power
Executive Summary
Januvia and Janumet are misbranded, FDA tells Merck in a warning letter noting that rodent safety studies for the sitagliptin diabetes drugs were 20 months behind schedule. The letter marks the first time FDA has used its FDAAA powers to take enforcement action against a pharma company for such a delay.
You may also be interested in...
Postmarketing Safety Studies: US FDA Defines ‘Good Cause’ For Missing Milestone Dates
A company is in violation for missed PMR milestones unless good cause has been demonstrated for noncompliance. New draft guidance, issued 16 years after the FDA gained the authority to require postmarketing safety studies, provides examples of when good cause exists and encourages sponsors to notify the agency in advance of missed deadlines.
FDA Postmarketing Study Oversight To Benefit From Informatics Upgrades
Changes in legacy DARRTS system, transition to new platform and standardized format for annual report submission should improve FDA's tracking of postmarketing requirements, agency tells Office of the Inspector General.
Post-Marketing Progress: Drug Industry Is Meeting Phase IV Commitments, FDA Says
FDA’s John Jenkins disputes accusations that the pharmaceutical industry does not take post-marketing studies seriously and that the agency is lax on enforcement. According to updated data from FDA, Phase IV studies are being completed in a timely manner, Jenkins argues – and when they aren’t, the agency is taking action.